Phase 1/2a Data Finds BI-1206 Antibody Restores Response to Rituximab in Patients With Relapsed Non-Hodgkin Lymphoma

Article

A CASI press release detailed data from a phase 1/2a study examining BI-1206 in combination with rituximab to treat patients with non-Hodgkin lymphoma.

BioInvent International AB recently announced interim data from a phase 1/2a trial of the antibody BI-1206 in combination with rituximab (Rituxan) to treat patients with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL), according to a press release from CASI Pharmaceuticals.

The data suggests that BI-1206, the novel anti-FcγRIIB antibody, restores the response to rituximab, an anti-CD20 monoclonal antibody, for patients with this form of NHL.

“The responses observed in 6 out of 9 patients are very encouraging and clearly suggest that BI-1206 may restore the response to rituximab in patients who have few treatment alternatives,” Martin Welschof, PhD, CEO of BioInvent, said in a press release. “The complete responses we have seen in 2 patients are particularly impressive and indicate that BI-1206 has the potential to significantly improve the lives of [patients with NHL] who have progressed after several lines of treatment.”

The trial saw 9 patients undergo induction therapy, with 6 patients showing either complete or partial responses. Of those, 2 patients continue to sustain a complete response at 12 and 24 months.

Considering dose-limiting toxicities were seen in this trial, the investigators implemented a new safety procedure to enable higher doses to be administered in the upcoming phase 1 dose-escalation part of the trial. When examining the 5 patients treated under this new safety protocol, no dose-limiting toxicities have been observed even with higher doses of BI-1206.

To this point, 15 patients have been recruited to the dose-escalation part of the trial. All of these patients have late-stage NHL that has failed conventional therapies, including a number of rituximab-containing therapies.

“Based on these results, we will now move to identify the recommended phase 2 dose for the phase 2a part of the trial and look forward to further evaluating the exciting potential of BI-1206 to bring much needed innovation to [patients with lymphoma],” explained Welschof.

BioInvent’s phase 1/2a study of BI-1206 to treat patients with NHL consists of 2 separate parts, with the first part utilizing dose-escalation cohorts with a 3 + 3 design. Phase 2a used an expansion cohort at the recommended phase 2a dose, featuring patients with mantle cell lymphoma.

“We continue to be excited about this anti-FcγRIIB antibody’s potential in restoring rituximab’s activity in [patients with NHL], and these results provided further encouraging evidence of its potential as a durable and safe treatment alternative,” Wei-Wu He, PhD, chairman and chief executive officer of CASI, said in a press release. “We remain encouraged by its potential application across multiple tumor types in many first-line treatments and in refractory settings and are excited to be taking an important step closer to making BI-1206 available to patients and healthcare providers across Greater China.”

Reference:

CASI Pharmaceuticals Partner, BioInvent, Presents Phase I/IIA Data That Suggests BI-1206 Restores Activity Of Rituximab In Relapsed Non-Hodgkin’s Lymphoma Patients [news release]. Rockville, Maryland and Beijing. Published January 28, 2021. Accessed February 1, 2021. https://www.prnewswire.com/news-releases/casi-pharmaceuticals-partner-bioinvent-presents-phase-iiia-data-that-suggests-bi-1206-restores-activity-of-rituximab-in-relapsed-non-hodgkins-lymphoma-patients-301217013.html

Recent Videos
Pallawi Torka, MD, with the Oncology Brothers presenting slides
Pallawi Torka, MD, with the Oncology Brothers presenting slides
Pallawi Torka, MD, with the Oncology Brothers presenting slides
Pallawi Torka, MD, with the Oncology Brothers presenting slides
Carla Casulo, MD, with the Oncology Brothers presenting slides
Carla Casulo, MD, with the Oncology Brothers presenting slides
Carla Casulo, MD, with the Oncology Brothers presenting slides
Carla Casulo, MD, with the Oncology Brothers presenting slides
Carla Casulo, MD, with the Oncology Brothers presenting slides
The approval for epcoritamab in patients with R/R follicular lymphoma was supported by encouraging efficacy findings from the phase 1/2 EPCORE NHL-1 trial.
Related Content